Safety Reading Notes

Read safety context beside the research guide.

The Nausea and vomiting source set includes safety-context rows around Psychiatric risk. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 41296368

Mapped evidence with interpretation limits: insufficient (2)

PubMed For Dummies Article

Nausea and vomiting Evidence Review: the long-form source walk-through

Quick read
  • Nausea and vomiting currently has 39 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 41296368
  • The evidence classes most visible in the row language are insufficient (30), preliminary human (6), and mechanistic or pharmacological (3). PMID 32899626
  • The study-design language most visible in the row language is Narrative or expert review (27), Human clinical study (5), Animal study (3), and other mapped categories (3). PMID 30627539
  • The repeated topics are Nausea and vomiting (8), Cannabinoids and nausea/vomiting research outcomes (6), Appetite and metabolic outcomes (5), nausea-related or inflammation-related outcomes (3), and other mapped categories (17), which tells the reader where to start opening PubMed and DOI links. PMID 39151115

Start with the research question

Nausea and vomiting is built from 39 source-backed evidence row(s) and 27 research source(s). The current evidence classes read as insufficient (30), preliminary human (6), and mechanistic or pharmacological (3), and the study-design language most often reads as Narrative or expert review (27), Human clinical study (5), Animal study (3), and other mapped categories (3). PMID 41296368

The row-level question is not simply whether Nausea and vomiting is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Nausea and vomiting (8), Cannabinoids and nausea/vomiting research outcomes (6), Appetite and metabolic outcomes (5), nausea-related or inflammation-related outcomes (3), and other mapped categories (17). PMID 39151115

Human evidence 6 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 11599601

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 34115951

Mechanistic evidence 3 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 23121618

Limits and uncertainty 30 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 37330589

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 25220897

Where this page has the most source density

The largest bucket surfaced for this page is Nausea and vomiting. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Cannabinoids and nausea/vomiting, which gives readers another way to see what the literature repeatedly circles. PMID 41296368

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 39151115

Bucket chapters: what the literature is circling

Nausea and vomiting

8 research sources 8 rows (480-487) Developed but mixed human research summary: insufficient (7), preliminary human (1)

Nausea and vomiting appears in rows studying Nausea and vomiting. It currently draws from 8 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41296368

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41296368

  • Evidence row 480

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or... PMID 41296368

  • Evidence row 487

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcom... PMID 18391612

Cannabinoids and nausea/vomiting

4 research sources 4 rows (233-379) Developed but mixed human research summary: insufficient (3), preliminary human (1)

Nausea and vomiting appears in rows studying Cannabinoids and nausea/vomiting. It currently draws from 4 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39151115

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 39151115

  • Evidence row 233

    THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: Cann... PMID 39151115

  • Evidence row 379

    THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: Can... PMID 27507945

nausea-related or inflammation-related outcomes

3 research sources 3 rows (43-131) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)

Nausea and vomiting appears in rows studying nausea-related or inflammation-related outcomes. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 30627539

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 30627539

  • Evidence row 43

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-relate... PMID 30627539

  • Evidence row 131

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or infla... PMID 23121618

Anxiety-related outcomes

2 research sources 2 rows (58-62) Early human research summary: insufficient (1), preliminary human (1)

Nausea and vomiting appears in rows studying Anxiety-related outcomes. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41296368

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41296368

  • Evidence row 58

    CBD studied for Anxiety-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: anxiety-related... PMID 41296368

  • Evidence row 62

    CBD studied for Anxiety-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes). PMID 39151115

Appetite and metabolic outcomes

2 research sources 2 rows (620-632) Early human research summary: insufficient (1), preliminary human (1)

Nausea and vomiting appears in rows studying Appetite and metabolic outcomes. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 32899626

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 32899626

  • Evidence row 620

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight,... PMID 32899626

  • Evidence row 632

    CBG studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 32795544

Appetite and metabolic outcomes

2 research sources 2 rows (39-83) Early human research summary: insufficient (1), preliminary human (1)

Nausea and vomiting appears in rows studying Appetite and metabolic outcomes. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 32899626

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 32899626

  • Evidence row 39

    THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metab... PMID 32899626

  • Evidence row 83

    THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabo... PMID 11599601

Cannabinoids and nausea/vomiting

2 research sources 2 rows (235-236) Mapped evidence with interpretation limits: insufficient (2)

Nausea and vomiting appears in rows studying Cannabinoids and nausea/vomiting. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 38478773

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 38478773

  • Evidence row 235

    Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: Can... PMID 38478773

  • Evidence row 236

    Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: Can... PMID 29168289

Psychiatric risk

2 research sources 2 rows (434-437) Mapped evidence with interpretation limits: insufficient (2)

Nausea and vomiting appears in rows studying Psychiatric risk. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41296368

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 41296368

  • Evidence row 434

    THC studied for Psychiatric risk; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 41296368

  • Evidence row 437

    THC studied for Psychiatric risk; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 39299947

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (6 row(s)), mechanistic evidence (3 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 41296368

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 39151115

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 38478773
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 29168289
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 38162115

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 41296368

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 39151115

Source-reading checklist for Nausea and vomiting

  1. Open the linked PubMed or DOI record. PMID 21175589
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 30720344
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 27507945
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 31161270
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 39299947

Source Notes

Nausea and vomiting source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 39

    THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 32899626

    Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
  2. Evidence row 43

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 30627539

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.
  3. Evidence row 58

    CBD studied for Anxiety-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: anxiety-related outcomes). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  4. Evidence row 62

    CBD studied for Anxiety-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes). PMID 39151115

    Evidence class: preliminary human; Study design: Human clinical study. Source: Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
  5. Evidence row 83

    THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes). PMID 11599601

    Evidence class: preliminary human; Study design: Human clinical study. Source: Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.
  6. Evidence row 126

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 34115951

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting.
  7. Evidence row 131

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 23121618

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation.
  8. Evidence row 176

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  9. Evidence row 195

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37330589

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis for morning sickness: areas for intervention to decrease cannabis consumption during pregnancy.
  10. Evidence row 205

    THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 25220897

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
  11. Evidence row 233

    THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: Cannabinoids and nausea/vomiting research outcomes). PMID 39151115

    Evidence class: preliminary human; Study design: Human clinical study. Source: Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
  12. Evidence row 235

    Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: Cannabinoids and nausea/vomiting research outcomes). PMID 38478773

    Evidence class: insufficient; Study design: Systematic review. Source: Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.
  13. Evidence row 236

    Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: Cannabinoids and nausea/vomiting research outcomes). PMID 29168289

    Evidence class: insufficient; Study design: Systematic review. Source: Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews.
  14. Evidence row 278

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 38162115

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain.
  15. Evidence row 377

    THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes). PMID 21175589

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Regulation of nausea and vomiting by cannabinoids.
  16. Evidence row 378

    THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes). PMID 30720344

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting.
  17. Evidence row 379

    THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes). PMID 27507945

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting.
  18. Evidence row 412

    CBD studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes). PMID 31161270

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Should Oncologists Recommend Cannabis?
  19. Evidence row 434

    THC studied for Psychiatric risk; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  20. Evidence row 437

    THC studied for Psychiatric risk; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 39299947

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.
  21. Evidence row 471

    THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  22. Evidence row 480

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  23. Evidence row 481

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 35982439

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.
  24. Evidence row 482

    THC studied for Nausea and vomiting; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 39151115

    Evidence class: preliminary human; Study design: Human clinical study. Source: Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
  25. Evidence row 483

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 39299947

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.
  26. Evidence row 484

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 35328765

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids: Therapeutic Use in Clinical Practice.
  27. Evidence row 485

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 27274310

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics.
  28. Evidence row 486

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 33974499

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Risk of QTc Prolongation with Antiemetics in the Palliative Care Setting: A Narrative Review.
  29. Evidence row 487

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 18391612

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemotherapy-induced nausea and vomiting.
  30. Evidence row 489

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes). PMID 10575285

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cancer cachexia and cannabinoids.
  31. Evidence row 501

    THC studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes). PMID 31161270

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Should Oncologists Recommend Cannabis?
  32. Evidence row 505

    THC studied for Sleep; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 33215831

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabis: are there any benefits?
  33. Evidence row 576

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 22150623

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid hyperemesis syndrome.
  34. Evidence row 620

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 32899626

    Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
  35. Evidence row 632

    CBG studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 32795544

    Evidence class: preliminary human. Source: Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use.
  36. Evidence row 686

    CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 32899626

    Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
  37. Evidence row 760

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 32899626

    Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
  38. Evidence row 796

    THCV studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 32899626

    Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
  39. Evidence row 1133

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17459108

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.